Investors

Press Releases

Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities
RSS
Show All